Stockscreener 앱 받기
47.00
1.49%
-0.6612
전일 마감가:
$47.66
열려 있는:
$47.33
하루 거래량:
1.18M
Relative Volume:
0.55
시가총액:
$3.71B
수익:
$170.10M
순이익/손실:
$-239.59M
주가수익비율:
-16.79
EPS:
-2.8
순현금흐름:
$-191.20M
1주 성능:
+5.67%
1개월 성능:
+27.37%
6개월 성능:
+14.32%
1년 성능:
-17.09%
1일 변동 폭
$45.60
$47.55
1주일 범위
$43.23
$48.48
52주 변동 폭
$30.04
$63.68
크리스퍼 테라퓨틱스 Stock (CRSP) Company Profile
명칭
Crispr Therapeutics Ag
전화
(617) 315-4600
주소
BAARERSTRASSE 14, ZUG
CRSP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
46.98 | 3.71B | 170.10M | -239.59M | -191.20M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.26 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
519.85 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
317.38 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.50 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
260.21 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
크리스퍼 테라퓨틱스 Stock (CRSP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-14 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2025-02-12 | 업그레이드 | TD Cowen | Sell → Hold |
| 2025-02-03 | 개시 | H.C. Wainwright | Buy |
| 2024-08-06 | 재확인 | Needham | Buy |
| 2024-08-02 | 개시 | Rodman & Renshaw | Buy |
| 2024-06-28 | 재개 | Guggenheim | Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-11 | 다운그레이드 | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | 개시 | Mizuho | Buy |
| 2023-08-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-05-30 | 개시 | William Blair | Outperform |
| 2023-04-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2023-03-17 | 개시 | Bryan Garnier | Buy |
| 2023-03-07 | 개시 | Robert W. Baird | Neutral |
| 2022-10-11 | 개시 | Morgan Stanley | Underweight |
| 2022-08-09 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-06-23 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-06-17 | 개시 | BMO Capital Markets | Outperform |
| 2022-04-28 | 개시 | Credit Suisse | Neutral |
| 2021-12-07 | 개시 | Cowen | Market Perform |
| 2021-10-19 | 개시 | SVB Leerink | Outperform |
| 2021-06-14 | 업그레이드 | Citigroup | Sell → Neutral |
| 2021-04-21 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-03-04 | 개시 | JMP Securities | Mkt Outperform |
| 2020-12-10 | 재확인 | Chardan Capital Markets | Buy |
| 2020-12-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-12-10 | 재확인 | Needham | Buy |
| 2020-12-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | 개시 | BofA Securities | Buy |
| 2020-07-28 | 재확인 | Needham | Buy |
| 2020-07-14 | 개시 | SunTrust | Buy |
| 2020-06-15 | 재확인 | Canaccord Genuity | Buy |
| 2020-03-05 | 개시 | Stifel | Hold |
| 2020-02-03 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-11-19 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-08-01 | 개시 | Jefferies | Buy |
| 2019-07-26 | 개시 | Canaccord Genuity | Buy |
| 2019-06-10 | 개시 | ROTH Capital | Buy |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-14 | 개시 | William Blair | Mkt Perform |
| 2019-01-28 | 다운그레이드 | Goldman | Buy → Neutral |
| 2019-01-22 | 다운그레이드 | Citigroup | Neutral → Sell |
모두보기
크리스퍼 테라퓨틱스 주식(CRSP)의 최신 뉴스
CRISPR Therapeutics AG (CRSP) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance
Traders Buy High Volume of Call Options on CRISPR Therapeutics (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It - MSN
From Now to 2032: Unpacking the Genome Editing Market's - openPR.com
CRISPR Therapeutics’ SWOT analysis: gene editing pioneer’s stock faces pivotal year - Investing.com
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement - Yahoo
Citizens JMP reiterates CRISPR Therapeutics stock rating on in-vivo progress - Investing.com
SG Americas Securities LLC Grows Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Shares Gap UpShould You Buy? - MarketBeat
Editas Medicine Is Great. Here's Why You Shouldn't Buy It. - The Motley Fool
25,341 Shares in CRISPR Therapeutics AG (NASDAQ:CRSP) Purchased by Avanza Fonder AB - MarketBeat
Can a $10,000 Investment in CRISPR Therapeutics Turn Into $1 Million? - 24/7 Wall St.
Millennium Management LLC Trims Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Equities Analysts Set Expectations for CRSP FY2026 Earnings - MarketBeat
Crispr extends gains for the seventh consecutive trading day - MSN
Crispr Therapeutics: Betting On A One-Shot Future (NASDAQ:CRSP) - Seeking Alpha
Trend Tracker for (CRSP) - news.stocktradersdaily.com
CRISPR Therapeutics (NASDAQ:CRSP) Trading Up 6%Here's What Happened - MarketBeat
Crispr Therapeutics AG: Stock Soars Amid Bullish Trends - MSN
CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock? - Yahoo Finance
Crispr Therapeutics: Early-Stage Research Updates Show Promise (NASDAQ:CRSP) - Seeking Alpha
Cantor Fitzgerald Weighs in on CRSP FY2026 Earnings - Defense World
CRISPR Therapeutics AG (CRSP) Rises Higher Than Market: Key Facts - Yahoo Finance
Crispr Therapeutics (CRSP) Rallies Amid FDA Fast-Tracking News - GuruFocus
Crispr extends gains for the seventh consecutive trading day (CRSP:NASDAQ) - Seeking Alpha
CRISPR Therapeutics AG shareholders approve key proposals By Investing.com - Investing.com South Africa
CRISPR Therapeutics AG Shareholders Approve Key Proposals - TipRanks
CRISPR Therapeutics AG shareholders approve key proposals - Investing.com
Cathie Wood Just Flagged The Start Of A Biotech Revolution: These 2 Stocks With 10x Potential Are Leading It - Benzinga
Wealth Enhancement Advisory Services LLC Has $1.08 Million Stake in CRISPR Therapeutics AG (NASDAQ:CRSP) - Defense World
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know - MSN
CRISPR Therapeutics (NasdaqGM:CRSP) Sees 16% Stock Price Surge Over Last Month - simplywall.st
Crispr: Shares Very Undervalued, as Early-Stage Pipeline Makes Progress and Casgevy Launch Underway - Morningstar
CRSP Sees Significant Increase in Bullish Option Activity | CRSP Stock News - GuruFocus
Crispr Therapeutics call volume above normal and directionally bullish - TipRanks
CRISPR Therapeutics (CRSP) Up 11.1% Since Last Earnings Report: Can It Continue? - Yahoo Finance
CRISPR Therapeutics AG (NASDAQ:CRSP) Stake Raised by Green Alpha Advisors LLC - MarketBeat
Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline? - sharewise
Promising Growth and Diversification Drive Buy Rating for Crispr Therapeutics AG - TipRanks
Can CRISPR Build On Casgevy's Success With Its In Vivo Pipeline? - Barchart.com
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by Voloridge Investment Management LLC - MarketBeat
Capital Market Strategies LLC Buys 9,652 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Q2 EPS Forecast for CRISPR Therapeutics Increased by Analyst - MarketBeat
크리스퍼 테라퓨틱스 (CRSP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
크리스퍼 테라퓨틱스 주식 (CRSP) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Kulkarni Samarth | Chief Executive Officer |
Mar 21 '25 |
Sale |
41.23 |
10,031 |
413,578 |
195,085 |
| Bruno Julianne | Chief Operating Officer |
Mar 21 '25 |
Sale |
41.23 |
1,714 |
70,668 |
10,544 |
| Prasad Raju | Chief Financial Officer |
Mar 21 '25 |
Sale |
41.23 |
2,197 |
90,582 |
16,767 |
| KASINGER JAMES R. | General Counsel and Secretary |
Mar 21 '25 |
Sale |
41.23 |
3,185 |
131,318 |
81,729 |
| Prasad Raju | Chief Financial Officer |
Mar 17 '25 |
Sale |
41.80 |
3,762 |
157,252 |
12,714 |
| Kulkarni Samarth | Chief Executive Officer |
Mar 11 '25 |
Sale |
42.42 |
9,973 |
423,055 |
180,890 |
| Kulkarni Samarth | Chief Executive Officer |
Mar 12 '25 |
Sale |
43.32 |
4,462 |
193,294 |
185,428 |
| KASINGER JAMES R. | General Counsel and Secretary |
Mar 11 '25 |
Sale |
42.42 |
2,850 |
120,897 |
77,530 |
| KASINGER JAMES R. | General Counsel and Secretary |
Mar 12 '25 |
Sale |
43.32 |
1,116 |
48,345 |
78,664 |
| Bruno Julianne | Chief Operating Officer |
Mar 11 '25 |
Sale |
42.42 |
1,198 |
50,819 |
8,263 |
0.78%
1.26%
자본화:
|
볼륨(24시간):